445 related articles for article (PubMed ID: 33692776)
1. TGR5 Regulates Macrophage Inflammation in Nonalcoholic Steatohepatitis by Modulating NLRP3 Inflammasome Activation.
Shi Y; Su W; Zhang L; Shi C; Zhou J; Wang P; Wang H; Shi X; Wei S; Wang Q; Auwerx J; Schoonjans K; Yu Y; Pan R; Zhou H; Lu L
Front Immunol; 2020; 11():609060. PubMed ID: 33692776
[TBL] [Abstract][Full Text] [Related]
2. Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition.
Kim SH; Kim G; Han DH; Lee M; Kim I; Kim B; Kim KH; Song YM; Yoo JE; Wang HJ; Bae SH; Lee YH; Lee BW; Kang ES; Cha BS; Lee MS
Autophagy; 2017 Oct; 13(10):1767-1781. PubMed ID: 28933629
[TBL] [Abstract][Full Text] [Related]
3. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation.
Liu J; Wang T; He K; Xu M; Gong JP
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):8158-8167. PubMed ID: 31599445
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.
He K; Zhu X; Liu Y; Miao C; Wang T; Li P; Zhao L; Chen Y; Gong J; Cai C; Li J; Li S; Ruan XZ; Gong J
Oncotarget; 2017 Jun; 8(23):37657-37672. PubMed ID: 28499273
[TBL] [Abstract][Full Text] [Related]
5. Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release.
Pan J; Ou Z; Cai C; Li P; Gong J; Ruan XZ; He K
Cell Immunol; 2018 Oct; 332():111-120. PubMed ID: 30103942
[TBL] [Abstract][Full Text] [Related]
6. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
Huang S; Wu Y; Zhao Z; Wu B; Sun K; Wang H; Qin L; Bai F; Leng Y; Tang W
Metabolism; 2021 Jul; 120():154797. PubMed ID: 33984334
[TBL] [Abstract][Full Text] [Related]
7. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder.
Hu J; Wang H; Li X; Liu Y; Mi Y; Kong H; Xi D; Yan W; Luo X; Ning Q; Wang X
Theranostics; 2020; 10(21):9702-9720. PubMed ID: 32863955
[No Abstract] [Full Text] [Related]
8. Sweroside Prevents Non-Alcoholic Steatohepatitis by Suppressing Activation of the NLRP3 Inflammasome.
Yang G; Jang JH; Kim SW; Han SH; Ma KH; Jang JK; Kang HC; Cho YY; Lee HS; Lee JY
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316419
[TBL] [Abstract][Full Text] [Related]
9. Restraint stress promotes nonalcoholic steatohepatitis by regulating the farnesoid X receptor/NLRP3 signaling pathway.
Yang F; Lv XT; Lin XL; Wang RH; Wang SM; Wang GE
Acta Biochim Biophys Sin (Shanghai); 2023 Dec; 55(12):1961-1971. PubMed ID: 37997375
[TBL] [Abstract][Full Text] [Related]
10. Gpbar-1/cAMP/PKA signaling mitigates macrophage-mediated acute cholestatic liver injury via antagonizing NLRP3-ASC inflammasome.
Zhuang L; Jia N; Zhang L; Zhang Q; Antwi SO; Sartorius K; Wu K; Sun D; Xi D; Lu Y
Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167266. PubMed ID: 38806072
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF-κB/NLRP3 inflammasome circuit.
Flores-Costa R; Duran-Güell M; Casulleras M; López-Vicario C; Alcaraz-Quiles J; Diaz A; Lozano JJ; Titos E; Hall K; Sarno R; Masferrer JL; Clària J
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28263-28274. PubMed ID: 33106416
[TBL] [Abstract][Full Text] [Related]
12. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
Wang Q; Zhou H; Bu Q; Wei S; Li L; Zhou J; Zhou S; Su W; Liu M; Liu Z; Wang M; Lu L
J Hepatol; 2022 Aug; 77(2):312-325. PubMed ID: 35292349
[TBL] [Abstract][Full Text] [Related]
13. Bile Acids Control Inflammation and Metabolic Disorder through Inhibition of NLRP3 Inflammasome.
Guo C; Xie S; Chi Z; Zhang J; Liu Y; Zhang L; Zheng M; Zhang X; Xia D; Ke Y; Lu L; Wang D
Immunity; 2016 Oct; 45(4):802-816. PubMed ID: 27692610
[TBL] [Abstract][Full Text] [Related]
14. NLRP3 inflammasome activation is required for fibrosis development in NAFLD.
Wree A; McGeough MD; Peña CA; Schlattjan M; Li H; Inzaugarat ME; Messer K; Canbay A; Hoffman HM; Feldstein AE
J Mol Med (Berl); 2014 Oct; 92(10):1069-82. PubMed ID: 24861026
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis.
Povero D; Lazic M; McBride C; Ambrus-Aikelin G; Stansfield R; Johnson CD; Santini AM; Pranadinata RF; McGeough MD; Stafford JA; Hoffman HM; Feldstein AE; Veal JM; Bain G
J Pharmacol Exp Ther; 2023 Aug; 386(2):242-258. PubMed ID: 37308266
[TBL] [Abstract][Full Text] [Related]
16. Deficiency of the Purinergic Receptor 2X
Blasetti Fantauzzi C; Menini S; Iacobini C; Rossi C; Santini E; Solini A; Pugliese G
Oxid Med Cell Longev; 2017; 2017():8962458. PubMed ID: 29270247
[TBL] [Abstract][Full Text] [Related]
17. Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice.
Lebeaupin C; Vallée D; Rousseau D; Patouraux S; Bonnafous S; Adam G; Luciano F; Luci C; Anty R; Iannelli A; Marchetti S; Kroemer G; Lacas-Gervais S; Tran A; Gual P; Bailly-Maitre B
Hepatology; 2018 Aug; 68(2):515-532. PubMed ID: 29457838
[TBL] [Abstract][Full Text] [Related]
18. Chenodeoxycholic acid activates NLRP3 inflammasome and contributes to cholestatic liver fibrosis.
Gong Z; Zhou J; Zhao S; Tian C; Wang P; Xu C; Chen Y; Cai W; Wu J
Oncotarget; 2016 Dec; 7(51):83951-83963. PubMed ID: 27924062
[TBL] [Abstract][Full Text] [Related]
19. Galectin-3 regulates inflammasome activation in cholestatic liver injury.
Tian J; Yang G; Chen HY; Hsu DK; Tomilov A; Olson KA; Dehnad A; Fish SR; Cortopassi G; Zhao B; Liu FT; Gershwin ME; Török NJ; Jiang JX
FASEB J; 2016 Dec; 30(12):4202-4213. PubMed ID: 27630169
[TBL] [Abstract][Full Text] [Related]
20. NLRP3 Inflammasome Formation and Activation in Nonalcoholic Steatohepatitis: Therapeutic Target for Antimetabolic Syndrome Remedy FTZ.
Chen Y; He X; Yuan X; Hong J; Bhat O; Li G; Li PL; Guo J
Oxid Med Cell Longev; 2018; 2018():2901871. PubMed ID: 30140364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
